Fig. 6: NSCLC xenograft growth is decreased upon knockdown of KRAS via the anti-EGFR-mAB-protamine (P)/siRNA/P nanostructures.
From: Targeted siRNA nanocarrier: a platform technology for cancer treatment
A Treatment scheme of the in vivo experiments. B–F Results of systemic in vivo application of targeted nanocarriers on A549 and SK-LU1 xenograft tumours. B Tumour growth curves for A549 (means–SEM). C Tumour growth curves for SK-LU1 (means–SEM). Both tumour growth curves show significant reduction of tumour growth in anti-KRAS siRNA treatment groups. D, E Size of excised tumours at the end of the respective experiments (X = individual tumours in anti-KRAS siRNA group were treated to extinction). F, G Weight statistics of the excised tumours (g, gram). H Proof of KRAS oncogene knockdown in excised tumour tissue by KRAS western blot ex vivo. Cntr control scrambled siRNA. *denote significant differences between groups (p < 0.05, two-sided t-test).
